Antidepressants May Be Effective for Small Cell Lung Cancer

This article originally appeared here.
Share this content:
Bioinformatics Approach IDs Approved Drugs for Repurposing
Bioinformatics Approach IDs Approved Drugs for Repurposing

(HealthDay News) -- Bioinformatics-based drug approaches have identified U.S. Food and Drug Administration-approved drugs and a novel class of molecules that can be repurposed to treat patients with small cell lung cancer (SCLC), according to research published online Sept. 26 in Cancer Discovery.

Nadine S. Jahchan, Ph.D., from Stanford University in California, and colleagues used a systematic drug repositioning bioinformatics approach querying a large compendium of gene expression profiles to identify candidate FDA-approved drugs to treat SCLC.

Related: Lung Cancer Treatment Regimens

The researchers found that tricyclic antidepressants and related molecules potently induced apoptosis in both chemonaive and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endogenous tumors from a mouse model for human SCLC.

Stress pathways were activated by the candidate drugs to induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein-coupled receptors. Growth of other neuroendocrine tumors was inhibited by the candidate drugs, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.

"These experiments identify novel targeted strategies that can be rapidly evaluated in patients with neuroendocrine tumors through the repurposing of approved drugs," the authors write.

Several authors disclosed financial ties to NuMedii, the developer of these drugs, and are named on patents for the use of specific tricyclic antidepressants in neuroendocrine tumors.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs